MNTA: Dew, I am glad you are so resolute in your positve analysis of the Goldman presentation. I am long MNTA because of the high reward/risk ratio. I am not as skillful at reading the tea-leaves when it comes to MNTA presentations as I came away feeling there was some trepidation in Craig Wheelers tone of voice regarding the discussion regarding timeliness in FDA decision. Is management really that in the dark when it comes to final FDA responses? My primary fear is FDA drags its feet and becomes handicapped because of politics. But If I am to believe that the only remaining roadblock is the integrity of the bulk heparin supply then I will hold on to my shares tightly. Safety of the heparin supply and supply chain should be a slam dunk for the company. It is only a matter of time. Heck they were the only ones who could identify the contaminants during last years China heparin contamination. How in the heck did shark cartilage get into the supply? That question even MNTA can not answer. lol
Market Data 
Markets 
AI
